Modulo Bio simulates the neuroimmune system to find medication candidates that target microglia cells. The organization's proprietary neuroimmune platform combines the most recent developments in stem cell biology and neuroscience with software, automation, and artificial intelligence to create novel treatments.
Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.
The University of Gothenburg, established in 1891, is a non-endowment university located in Gothenburg, Sweden. It is dedicated to societal advancement and aims to foster a sustainable world. The university engages actively in public discourse and collaborates with the surrounding community through ongoing dialogues and knowledge exchange, both nationally and internationally. Among its various faculties, the School of Business, Economics and Law plays a significant role in the university's mission to contribute to societal development and economic understanding. The management of the university's assets is overseen by its board members, ensuring a structured approach to its operations and initiatives.
GLX Analytix is a biotechnology company focused on advancing personalized medicine through a proprietary class of blood biomarkers combined with artificial intelligence. The company specializes in early diagnosis and monitoring of chronic diseases, providing clinicians with tools to track disease progression, monitor treatment responses, and predict flare-ups. By enhancing patient empowerment and enabling self-monitoring, GLX Analytix aims to optimize treatment plans and improve health outcomes. The company collaborates with institutions like Harvard Medical / Wyss Diagnostic Accelerator and has received recognition for its innovative approach, highlighting its potential to significantly impact patient lives globally.
C2N Diagnostics, LLC is a privately held protein diagnostic and therapeutic discovery company targeting progressive neurodegeneration. They formed in late 2007 by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, and LifeTech Research, a Maryland-based technology research and commercialization firm (www.lifetechresearch.com). They reside at the Center for Emerging Technologies in St. Louis.
NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.
RetiSpec is developing a non-invasive eye scanner for early detection of Alzheimer’s Disease pathology years before symptoms occur, so that clinicians can intervene with emerging therapeutics early, when there’s a chance of actually impacting the disease.
Coya Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies that enhance the function of regulatory T cells (Tregs) in vivo. It is focused on creating proprietary medicinal products, including allogeneic Treg-derived exosome therapeutics and novel biologics. The company aims to address various medical conditions, including neurodegenerative, autoimmune, and metabolic diseases, through its multi-modality Treg therapies.
NeuroAge Therapeutics is a longevity biotech firm that develops new medications to rejuvenate biological brain aging and treat neurodegenerative illnesses utilizing a machine learning aging clock technology.
Superfluid DX is focused on developing a translational science and data analysis platform that leverages cell-free mRNA to diagnose neurodegenerative and other diseases. The company utilizes innovative molecular diagnostics technology to extract genetic information from blood samples, specifically analyzing tissue-specific cell-free circulating RNA. This novel approach aims to enhance disease monitoring by enabling early detection of health issues and providing physicians with valuable insights into a patient's health status versus disease state. Through its advanced testing methods, Superfluid DX seeks to improve patient outcomes by facilitating timely interventions and better management of various medical conditions.
GliaPharm SA is a Swiss biotechnology company focused on developing treatments for neurological and psychiatric disorders. Founded in 2016 and based in Geneva, the company utilizes its GliaX technology platform to identify drugs that target the activity of glial cells, which are essential support cells for neurons. This innovative approach aims to enhance brain metabolism in pathological conditions. GliaPharm employs high throughput screening technologies and conducts metabolic tests on both in vitro primary brain cell cultures and in vivo rodent models to evaluate compounds. The company addresses various neurological conditions, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS), and collaborates with contract research organizations to advance its drug development and regulatory processes. With a vision to lead in glia-mediated therapies, GliaPharm seeks to provide new neuroprotective agents that support cognitive function in patients.
Imeka is a developer of advanced brain imaging technology aimed at enhancing research capabilities in the medical field. The company's platform leverages high-resolution MRI and deep learning algorithms to provide insights into critical neurological aspects such as neuroinflammation, demyelination, and axonal loss. By offering comprehensive imaging solutions, including the potential integration of PET and SPECT preclinical cardiac analysis, Imeka enables pharmaceutical companies to better understand brain connectivity and the intricacies of white matter. This innovative approach supports researchers in maximizing the value of their medical images, ultimately contributing to advancements in neuroscience and related therapeutic areas.
CuraSen Therapeutics is a biopharmaceutical company that develops orphan drugs to treat neurodegenerative diseases, including Parkinson's disease, and Alzheimer's disease.
BrainScope is a medical neurotechnology company focused on enhancing brain health through innovative assessment tools. Established in 2010 and headquartered in Bethesda, Maryland, the company develops hand-held, non-invasive instruments designed for rapid, accurate evaluation of brain function at the point of care. Its flagship product, the BrainScope One system, is an FDA-cleared, portable device that utilizes EEG technology to assess head-injured patients. This system allows healthcare professionals to quickly triage patients for conditions such as brain bleeds and concussions, facilitating timely decisions regarding the need for further imaging, such as CT scans. By combining advanced digital signal processing and proprietary algorithms with a database of brainwave recordings, BrainScope provides objective diagnostic insights that enhance patient care.
Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on the research, development, and manufacturing of innovative diagnostic tools for the detection of neurological diseases. Established in 2015 and headquartered in Taipei, Taiwan, with additional locations in China and Japan, the company specializes in advanced imaging techniques, notably the 18F-PM-PBB3 tau positron-emission tomography (PET) imaging tracer. This tracer aids in diagnosing tauopathies and supports the development of therapeutic programs for conditions such as Alzheimer's disease, Parkinson's disease, and dementia. Additionally, Aprinoia manufactures an alpha-synuclein PET imaging tracer. The company's mission is to enhance brain health and improve clinical outcomes for patients suffering from various neurodegenerative diseases by leveraging precision medicine to target harmful protein aggregates involved in these conditions.
Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.
ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.
ALZpath is a biotechnology company that provides novel diagnostic solutions for Alzheimer’s disease.
Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.
Cognito Therapeutics is a clinical-stage neurotechnology company based in San Francisco, focused on developing disease-modifying treatments for neurodegenerative disorders, particularly Alzheimer's Disease. Founded by MIT professors Li-Huei Tsai and Ed Boyden, the company utilizes a non-invasive neuromodulation platform that induces brain wave oscillations to reactivate the brain's immune system. This innovative approach aims to address core symptoms of Alzheimer's by targeting and reducing the accumulation of amyloid plaques and tau tangles. Cognito's primary therapy is currently undergoing a pivotal study and has received designation as a Breakthrough Device from the FDA, highlighting its potential to significantly impact the treatment landscape for Alzheimer's patients.
(Epi-)genetic approaches addressing molecular initiation events and key events of adverse outcome pathways driving pathologies like neurodegeneration, cancer and immune-dysfunction.
Imaginostics specializes in developing advanced diagnostic tools aimed at enhancing precision medicine for clinicians and drug developers. Utilizing proprietary MRI physics-based technology, the company offers significantly improved vascular imaging and quantitative assessments of vascular structure, function, and leakage. This innovative approach not only produces images ten times better than traditional methods but is also compatible with existing MRI scanners and utilizes a safe iron supplement for contrast instead of toxic gadolinium. Imaginostics provides biomarker solutions through collaborations with contract research organizations and engages in pre-clinical and clinical research across various focus areas, working alongside leading researchers at prestigious institutions. The company's noninvasive imaging technology is designed to aid in the diagnosis of neurological disorders, facilitate safe vascular visualization for renal patients, and support acute diagnostics for conditions like traumatic brain injury or stroke, ultimately enabling hospitals to monitor disease progression and evaluate drug effects efficiently.
Superfluid DX is focused on developing a translational science and data analysis platform that leverages cell-free mRNA to diagnose neurodegenerative and other diseases. The company utilizes innovative molecular diagnostics technology to extract genetic information from blood samples, specifically analyzing tissue-specific cell-free circulating RNA. This novel approach aims to enhance disease monitoring by enabling early detection of health issues and providing physicians with valuable insights into a patient's health status versus disease state. Through its advanced testing methods, Superfluid DX seeks to improve patient outcomes by facilitating timely interventions and better management of various medical conditions.
Quanterix Corporation is a life sciences company focused on advancing precision health through its innovative digital immunoassay platform, Simoa. This ultra-sensitive technology allows for the detection of protein biomarkers in extremely low concentrations within biological samples, such as blood and serum, which traditional immunoassay methods cannot identify. Quanterix's solutions enable rapid and accurate quantification of individual proteins and small molecules, addressing various unmet medical needs in clinical diagnostics, drug development, and life science research. By improving the ability to detect disease at earlier stages, Quanterix aims to enhance prognosis and treatment precision, ultimately contributing to better health outcomes and quality of life for individuals. The company's product offerings include a range of assay kits, instruments, and specialized services designed to meet the demands of researchers and healthcare professionals.
Optina Diagnostics Inc. is a diagnostics company based in Montréal, Canada, founded in 2010. It specializes in the early detection of Alzheimer's disease through innovative hyperspectral imaging technology that examines the retina. By employing non-invasive diagnostic tests, Optina Diagnostics identifies key biomarkers, such as beta-amyloid plaques, which are crucial for assessing patients' health and disease risk. The company's advanced imaging systems also aid in the detection of age-related macular degeneration and ocular diabetic retinopathy, providing physicians with critical information that enables timely and appropriate patient care. Through its focus on retinal features and artificial intelligence, Optina Diagnostics aims to transform the assessment of brain health and address under-diagnosed diseases.
MindImmune Therapeutics, Inc. is a pharmaceutical company focused on developing innovative drugs that target the immune system to address diseases of the central nervous system, including Alzheimer’s and Huntington’s diseases, as well as pain and psychiatric disorders. Recognizing the critical role of immune system dysfunction in brain health, MindImmune aims to leverage this connection to create effective therapeutic options. Founded in 2016 and headquartered in Kingston, Rhode Island, the company is establishing partnerships with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to enhance its research and development efforts. MindImmune is committed to advancing its drug development programs within the growing Rhode Island academic neuroscience ecosystem.
Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.
NeuroVision Imaging LLC is a neuroscience company that specializes in developing digital imaging and diagnostic solutions for Alzheimer’s disease and eye care. The company focuses on creating diagnostic tests and biomarkers to detect and monitor amyloid pathology associated with Alzheimer’s disease, utilizing a novel retinal imaging technology currently employed in various global clinical trials. NeuroVision Imaging also offers data aggregation services, analysis, biostatistics, and the application of machine learning algorithms to extensive datasets of images and biomarker information to enhance the understanding and predictive capabilities related to neurodegenerative diseases. Founded in 2010, the company is headquartered in Sacramento, California, and serves clients both in the United States and internationally.
C. Light Technologies, Inc. is a neurotechnology company based in Berkeley, California, specializing in eye tracking technology for neurological health assessment. Founded in 2014, the company has developed a retinal eye-tracking platform that utilizes advanced machine learning algorithms and a highly accurate eye tracker. This technology is particularly focused on monitoring multiple sclerosis by measuring neurological activity through imaging the retina. C. Light's clinical devices combine sophisticated hardware and software to enhance the diagnosis and monitoring of neurodegenerative diseases, enabling healthcare professionals to assess neurological health with greater precision.
NeuroVision Imaging LLC is a neuroscience company that specializes in developing digital imaging and diagnostic solutions for Alzheimer’s disease and eye care. The company focuses on creating diagnostic tests and biomarkers to detect and monitor amyloid pathology associated with Alzheimer’s disease, utilizing a novel retinal imaging technology currently employed in various global clinical trials. NeuroVision Imaging also offers data aggregation services, analysis, biostatistics, and the application of machine learning algorithms to extensive datasets of images and biomarker information to enhance the understanding and predictive capabilities related to neurodegenerative diseases. Founded in 2010, the company is headquartered in Sacramento, California, and serves clients both in the United States and internationally.
LEXEO Therapeutics is a biotechnology company that specializes in the development of gene therapies, particularly those utilizing adeno-associated virus (AAV) technology. The company’s pipeline includes both rare and non-rare monogenic diseases, with a strong emphasis on hereditary and acquired conditions that present significant unmet medical needs. LEXEO's lead programs and preclinical candidates are primarily developed in collaboration with Weill Cornell Medicine’s Department of Genetic Medicine. The company aims to advance its clinical programs toward commercialization while maintaining an ongoing research partnership with Weill Cornell to enhance its preclinical efforts. Through its innovative approach, LEXEO Therapeutics seeks to transform the treatment landscape for diseases that impose a substantial burden on patients and society.
C2N Diagnostics, LLC is a privately held protein diagnostic and therapeutic discovery company targeting progressive neurodegeneration. They formed in late 2007 by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, and LifeTech Research, a Maryland-based technology research and commercialization firm (www.lifetechresearch.com). They reside at the Center for Emerging Technologies in St. Louis.
NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.
Biological Dynamics Inc. is a healthcare company based in San Diego, California, focused on enhancing global health outcomes through early disease detection. The company has developed a proprietary technology platform that enables the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This platform facilitates the analysis of native-state biomarkers and nanoparticles, supporting multiomics applications. Biological Dynamics specializes in cancer detection and offers a range of services, including the TR(ACE) Assay for monitoring treatment responses and tumor burdens, as well as liquid biopsy testing for personalized medicine. Additionally, the company provides clinical laboratory services, including molecular and next-generation sequencing, and has programs aimed at drug development in areas such as Alzheimer's disease. Founded in 2008, Biological Dynamics is committed to utilizing machine learning and its advanced technology to address various health challenges, including autoimmune diseases, transplant rejection, and traumatic brain injury.
Vaccinex has developed an antibody discovery platform that enables efficient mammalian cell-based expression for expression of large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface envelope of a mammalian virus and the cell surface membrane of the infected cell. This allows them to combine the advantages of virus panning and cell sorting into one seamless selection process. This technology enables the rapid selection of 1010 antibody combinations and thus selection of high affinity leads with varied frameworks that recognize multiple epitopes. It is based in Rochester, New York.
DiamiR is mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for early detection and monitoring of brain and synaptic health conditions, including mild cognitive impairment and Alzheimer’s disease, to enable earlier intervention and better planning of care.
RetiSpec is developing a non-invasive eye scanner for early detection of Alzheimer’s Disease pathology years before symptoms occur, so that clinicians can intervene with emerging therapeutics early, when there’s a chance of actually impacting the disease.
AgeneBio, Inc. is a neuroscience pharmaceutical company founded in 2008 by Dr. Michela Gallagher, focused on developing therapeutic products for Alzheimer's disease, dementia, and other memory disorders. The company's primary targets include Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). AgeneBio aims to create innovative therapeutics that prevent neurodegeneration and preserve cognitive function in patients at risk for neurological and psychiatric conditions. By addressing the symptomatic pre-dementia stage of Alzheimer's disease and other related disorders, AgeneBio seeks to provide effective treatments for individuals facing these challenging health issues. The company is headquartered in Indianapolis, Indiana, and engages in global research and development efforts through various partnerships.
Oryzon Genomics S.A. is a clinical phase biopharmaceutical company focused on the discovery and development of epigenetics-based therapeutics aimed at treating cancer and central nervous system (CNS) disorders. The company is advancing its clinical pipeline with two key compounds currently in Phase II trials: iadademstat, a selective LSD1 inhibitor designed for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor targeting neurological diseases. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor that is in preclinical stages for non-oncological conditions. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, Oryzon Genomics utilizes its epigenetic platform to identify and validate biomarkers and therapeutic targets, facilitating the creation of advanced and personalized therapies.
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and addressing neurodegenerative diseases. The company's lead candidate, ATH-1017, is a small hepatocyte growth factor/MET activator designed to penetrate the blood-brain barrier and is currently undergoing various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. Additionally, Athira is advancing other candidates, including ATH-1019, which is in preclinical development for depression, and ATH-1018, aimed at treating peripheral neuropathy. Founded in 2011 and originally named M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its commitment to innovative therapies that positively impact individuals affected by brain disorders.
Oryzon Genomics S.A. is a clinical phase biopharmaceutical company focused on the discovery and development of epigenetics-based therapeutics aimed at treating cancer and central nervous system (CNS) disorders. The company is advancing its clinical pipeline with two key compounds currently in Phase II trials: iadademstat, a selective LSD1 inhibitor designed for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor targeting neurological diseases. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor that is in preclinical stages for non-oncological conditions. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, Oryzon Genomics utilizes its epigenetic platform to identify and validate biomarkers and therapeutic targets, facilitating the creation of advanced and personalized therapies.
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and addressing neurodegenerative diseases. The company's lead candidate, ATH-1017, is a small hepatocyte growth factor/MET activator designed to penetrate the blood-brain barrier and is currently undergoing various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. Additionally, Athira is advancing other candidates, including ATH-1019, which is in preclinical development for depression, and ATH-1018, aimed at treating peripheral neuropathy. Founded in 2011 and originally named M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its commitment to innovative therapies that positively impact individuals affected by brain disorders.
Tetra Therapeutics Inc. is a clinical-stage biotechnology company focused on developing pharmaceutical drugs that target phosphodiesterase (PDE) sub-type inhibitors for various neurological and non-neurological disorders. The company is known for its lead product, BPN14770, which aims to enhance brain synaptic function through the PKA-CREB pathway, addressing significant conditions such as Alzheimer's disease, schizophrenia, and developmental disabilities. Tetra Therapeutics also works on therapeutic solutions for individuals affected by traumatic brain injury and other psychiatric and neurodevelopmental disorders. Founded in 2011 and based in Grand Rapids, Michigan, the company was previously known as Tetra Discovery Partners, changing its name in August 2019. Tetra Therapeutics has established a strategic collaboration with Shionogi & Co., Ltd., and operates as a subsidiary of the same entity.
NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.
Oryzon Genomics S.A. is a clinical phase biopharmaceutical company focused on the discovery and development of epigenetics-based therapeutics aimed at treating cancer and central nervous system (CNS) disorders. The company is advancing its clinical pipeline with two key compounds currently in Phase II trials: iadademstat, a selective LSD1 inhibitor designed for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor targeting neurological diseases. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor that is in preclinical stages for non-oncological conditions. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, Oryzon Genomics utilizes its epigenetic platform to identify and validate biomarkers and therapeutic targets, facilitating the creation of advanced and personalized therapies.
Metabolic Solutions Development Company, LLC is a biopharmaceutical firm focused on discovering and developing innovative therapeutics for metabolic diseases associated with aging. Established in 2006 and located in Kalamazoo, Michigan, the company is engaged in creating first-in-class oral therapeutics aimed at treating conditions such as type 2 diabetes, non-alcoholic steatohepatitis (NASH), polycystic kidney disease, and neurodegenerative disorders including Alzheimer's and Parkinson's diseases. Its key products include MSDC-0160 and MSDC-0602, which function as mitochondrial membrane modulators and insulin sensitizers. These agents target age-related mitochondrial dysfunction and aim to improve metabolic processes, thereby addressing insulin resistance and other related symptoms of metabolic syndrome.
Oryzon Genomics S.A. is a clinical phase biopharmaceutical company focused on the discovery and development of epigenetics-based therapeutics aimed at treating cancer and central nervous system (CNS) disorders. The company is advancing its clinical pipeline with two key compounds currently in Phase II trials: iadademstat, a selective LSD1 inhibitor designed for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor targeting neurological diseases. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor that is in preclinical stages for non-oncological conditions. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, Oryzon Genomics utilizes its epigenetic platform to identify and validate biomarkers and therapeutic targets, facilitating the creation of advanced and personalized therapies.
Metabolic Solutions Development Company, LLC is a biopharmaceutical firm focused on discovering and developing innovative therapeutics for metabolic diseases associated with aging. Established in 2006 and located in Kalamazoo, Michigan, the company is engaged in creating first-in-class oral therapeutics aimed at treating conditions such as type 2 diabetes, non-alcoholic steatohepatitis (NASH), polycystic kidney disease, and neurodegenerative disorders including Alzheimer's and Parkinson's diseases. Its key products include MSDC-0160 and MSDC-0602, which function as mitochondrial membrane modulators and insulin sensitizers. These agents target age-related mitochondrial dysfunction and aim to improve metabolic processes, thereby addressing insulin resistance and other related symptoms of metabolic syndrome.